Rigel Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
RIGL
CUSIP
766559702
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 766559702 since 12/18/2024, newest first.

Filer % of Class Filed
Armistice Capital, LLC 13G/A Amendment 1
9.0% 8/14/2026
Event 6/30/2026
Soleus Capital Master Fund, L.P. 13G/A Amendment 1
9.9% 8/13/2026
Event 6/30/2026
Armistice Capital, LLC 13G
6.9% 5/15/2026
Event 3/31/2026
Soleus Capital Master Fund, L.P. 13G
5.2% 5/7/2026
Event 5/6/2026
Vanguard Group Inc 13G/A Amendment 5 0% 3/27/2026
Event 3/13/2026
State Street Corp 13G 6.0% 2/9/2026
Event 12/31/2025
Morgan Stanley 13G/A Amendment 1
0.7% 10/7/2025
Event 9/30/2025
Soleus Capital Master Fund, L.P. 13G/A Amendment 4
3.7% 8/5/2025
Event 6/30/2025
Armistice Capital, LLC 13G/A Amendment 4
8.5% 5/15/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 17 7.7% 4/17/2025
Event 3/31/2025
Armistice Capital, LLC 13G/A Amendment 3
6.5% 2/14/2025
Event 12/31/2024
Soleus Capital Master Fund, L.P. 13G/A Amendment 3
6.4% 2/11/2025
Event 12/31/2024
Invesco Ltd. 13G/A Amendment 1 0% 2/7/2025
Event 12/31/2024
BlackRock, Inc. 13G 9.9% 2/5/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 8 104 k $5.01 M
2026 Q2 161 16.4 M $641 M
2026 Q1 156 16.0 M $433 M
2025 Q4 193 16.1 M $689 M
2025 Q3 172 15.0 M $426 M
2025 Q2 127 13.9 M $260 M
2025 Q1 125 14.0 M $252 M
2024 Q4 122 12.1 M $203 M
2024 Q3 97 11.9 M $193 M
2024 Q2 91 11.8 M $97.2 M